Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Algernon's "DMT Stroke Consultant" Dr/Professor David Nutt (a London resident) will be at the largest gathering of global Psychedelics experts to date in London on May 11 2022. There will likely be zero mention of Algernon because Dr. Nutt will be there to represent Compass Pathways. Yet another opportunity missed by the clown team at Algernon.
https://www.benzinga.com/markets/cannabis/22/04/26886825/a-landmark-gathering-of-psychedelics-executives-and-scientists-arrives-in-london-on-may-11
Threw you some Coins
Just a Reminder — $3.21 $AGNPF Cheap Options Cost they have gave themselves 1/21/2022 on 96,000 shares or so
It’s would be a Buy Signal - JMO - Won’t get there but close maybe real close and Insiders have gave upwards to $5 $AGNPF off the Public Market As Buys converted to USD
https://webfiles.thecse.com/Algernon_-_CSE_Form_11_-_Jan_2022.pdf?7OttxaohcZe4botaTSj0BzZpom7_zaEY=
Good points about setting up the domain.
Cut & paste the 2nd and 3rd paragraphs to < 200 words and send in the suggestions. You're obviously savvy about that stuff as we see here in posts.
Please...
We all can hope that things are handled better than some past issues. A GOOD SPLASH entering the NASDAQ is Important.!.
I think many folks are holding their cards to see what happens. LM-major-smoki-GVX-Kev-LS5-Ubuck-shell-folks on other MBs-you-me-etc.
Speculation. Your interest seems to imply you still have an investment (or agenda).
...GLTA...
Stone Age to \|/ Stone
One question I have for management is why in the world would you spend millions of dollars in the name of "advertising" and goo gobs of "infomercials" with the CEO's face plastered everywhere on the website in support of such infomercials (reminder of the spend rate) and the stock only continues to veer towards new all time lows at every turn? Ok, so now management made it's pitch and delivery on moving to Nasdaq with the belief the company will be exposed to a better classroom investors. Given that execution, what roll should their website play in the grand scheme of things?
Business 101 suggests you can drive more eyes to your website with the minimalist number of characters. 14 characters or less is the best target zone to accomplishing maximum drive/traffic. Therefore, why didn't management secure the most obvious website for the company moving forward with the rebranding of the company in 2018? Moreau spewed reels of infomercial stories about how he came up with the Algernon name and how he needed to convince Dr. Mark Williams (The Brainchild of All Things in Algernon's Pipeline Portfolio) it was a good idea. Ok, but again why did you not think or think at all it was a good idea to secure the shorter and more desirable domain name for the company from the outset for $10 freaking dollars! If you go out to Algernon's Twitter page the first thing you will see below the corporate logo at the top of the page is "AlgernonPharmaceuticals@AlgernonPharma.com". Do you see where the Pharma is abbreviated there? Surely, it proves a shorter version of the word Pharma is more desirable in their minds eye. Think of how hard is is for some to correctly spell the name Algernon and then how much harder it's likely to spell Pharmaceuticals. You have two words combined that are both hard to spell and twice as challenging for the average speller. There could be an argument made for Algernon not being hard to find on the web, but I'd contribute that to it currently being zero competitive traffic for the better version of a corporate domain name - algernonpharma.com.
The company has no control over that more effective version and what could be potentially trafficked to that website if it every becomes active on the web. If it were to become a space that is not complimentary to Algernon's corporate narrative I could see that posing legal expenses that surely would not be cheap. Thus, management needs to seriously consider what they want to control for it's messaging to the masses and the cost to doing their homework now versus compounding after the fact actions not in their favor.
Here's something else I found interesting in the world wide web realm. Algernon will list at nasdaq with a new abbreviated version of it's stock ticker. From AGNPF to AGNP. Less is better! Now do a web search for AGNP.com. What I gather is someone is targeting a specific company to buy their domain name at a price that suggests they mean business and have done their potential homework an advance of the offering. I firmly believe it has absolutely nothing to do with Algernon Pharmaceuticals but who knows? The bottom line is management need not be hardheaded and stubborn for fumbling the ball in regards to completely missing the mark for securing domain names (they should have secured both long and short version) from the outset. Moreau should check his pride at the door and do what needs to be done in this regard. They've already spending money on "ads" like drunken sailors. Make a real difference with your 21st Century Corporate B R A N D I N G. The better domain name is just Business 101. Management needs more savvy people for the upkeep of their corporate website/image.
Mark this post.
M$
Move to Nasdaq apparently set.
Price is apparently set and CR done. Long Longs get a bend over plan. I had hope for better. Shit hand is almost full while wish hand almost bare for long time investors/supporters.
Sure would have liked to see more positive announcements like this before this CR.
A nice string of PRs with successes would be nice over the next month(s) to help make a significant splash IPO, would be nice... We're sorta stuck again and need new/old investors to be attracted again.
Should happen, IMO...GLTA...
https://finance.yahoo.com/news/algernon-pharmaceuticals-announces-lead-chronic-110000973.html
Many bad 4 letter words that I can't post here.... I WAY too deep into this to sell. AGN better pull one heck of a rabbit out of a hat....
New F-1/A filing: @ $4.75 USD - Shares are going to more than double with matching warrants that will more than triple the outstanding shares to raise $8,000,000 USD. You are looking at 5 Million+ Fully Diluted Outstanding Shares at the in-the-money stock price of $5.23 USD.
5 Million Shares @ $5.23 USD = $26 Million USD Market Cap.
The company is effectively selling 100 to 1 reverse split shares @ 4 Cents per share. That's what the pending capital raise represents in real world terms for current shareholders.
I'm of the belief today's news release is to circumvent/camouflage/give cover to the latest plan. It was 9 million bid for capital now 8 million bid for capital.
It's my belief that break even for most 100 to 1 pre-reverse split shares is 30 Cent USD. Therefore, at 5 Million Outstanding Shares the company needs a market cap of $150 Million USD/$30 per share.
https://ih.advfn.com/stock-market/USOTC/algernon-pharmaceuticals-qb-AGNPD/stock-news/87896244/securities-registration-foreign-private-issuer-f-1
Best guess is AGNPF will see $2 per share again this year.
M$
You can take away the name Twitter and Social Media and replace them with Algernon and Biotech.
It's 4.5 cents for most portfolios not $4.5 USD.
Let me know when the stock is holding above $30 USD which is effectively 30 Cents.
M$
Good sign holding at these levels past couple month’s through all of the down side in the market’s … NAZ GLTA!
I agree. They (board of directors) are not worth it. Christopher Moreau drew himself a million dollar payday back in 2019. A million dollar CEO of a flailing and failing nano cap company in Penny World. Yeah, ^ that guy. From Pandemic to Recession to WWIII. Who cares about timelines? We're all gonna live forever!
Over The Cl!ff Crazy Ch!t @ Algernon Pharmaceuticals Inc.
M$
Outro
Has this company ghosted us? If the Covid for-play was the dinner date where we got all excited, no call the next day? We all waiting hopeful. Friends are all telling us to move on get on with our lives. They are not worth it.
The crazy part of the story is these two guys started out targeting a marijuana breathalyzer and switched gears to a medical breathalyzer for COVID-19. They have successfully done EGG ZACK LEE what shady leadership of Breathtec/Algernon set out to do in the beginning (Circa 2016). Which is chase after medical diseases. What shareholders got in return is a now flailing about virtual reality repurposed drugs nano cap (under $50M USD market cap) dilution machine stuck in pennyland. The successful startup company will circle back to the marijuana breathalyzer originally targeted. They will likely succeed where as Cannabix remains in prototype mode 8 years and counting. The value of Algernon lies within the value of the mindset of Algernon's management team. A team that has proven itself worth less and less as time rolls on. Algernon's medical device now lies in the hands of Cannabix under another name - in name only. You can bet Team Cobra will do what it can to mimic the successful start up with new stories down the road about detecting anything other than marijuana. The creative storytellers surrounding Team Cobra will surely strike (snake bite) a slew of newbies again and again.
Meet The Founders Of The $2.7 Million Startup Behind The New Covid Breathalyzer
www.forbes.com/sites/katiejennings/2022/04/15/meet-the-founders-of-the-27-million-startup-behind-the-new-covid-breathalyzer/?sh=59cf3cdc5165
Telling stories, diluting shareholders, and running out the clock is job #1 for Team Cobra.
M$
You had me going! I’m in Jamaica and took a quick look at the board.
Cheers
I think the UK MHRA will post any news on this site. IDK for sure butt watching (all the time, LOL) for an early opportunity. Posting there might be delayed.?.
https://www.isrctn.com/
...GLTA...
Lol TY! Thought maybe I was going to be Rich today :)))
Canada too ???
Regarding Ninnion's Ischemic Stroke clinical trial timeline:
55
AGN's Microdose / sub hallucinogenic DMT pre clinical work completed by Charles River Labs.
UK MHRA clinical trial applications filed Jan 2022
GMT DMT produced.
Hammerschmidt to run the Phase 1 CT and experts hired for planning and participation in Phase 2 ...
5 year timeline for the Ninion's, R+D and pre clinical work...
https://ir.algernonpharmaceuticals.com/news-events/press-releases/detail/5/algernon-pharmaceuticals-completes-manufacturing-of
"Anthony Rudd, MB, BChir, FRCP, CBE is an emeritus professor of Stroke Medicine at Kings College London and recently retired as a consultant stroke physician at Guy’s and St Thomas’ Hospital. He was the London Stroke Clinical Director from 2010-2019 and the National Clinical Director for Stroke for NHS England from 2013-2019, where he oversaw dramatic improvements in the paradigm of NHS stroke treatment."
"Dr. Robert Simister
Robert Simister MA MB BS PhD FRCP is a consultant neurologist and stroke physician as well as an honorary senior lecturer at University College London, where he also serves as the Clinical Lead for the Comprehensive Stroke Service and the Clinical Director of Stroke Medicine and Acute Neurology. Since 2019, he has been the Joint Clinical Director for the London Stroke Clinical Network."
https://ir.algernonpharmaceuticals.com/news-events/press-releases/detail/10/algernon-announces-positive-feedback-on-its-planned-phase
...GLTA...
Well...Well...Well. What Do We Have Here?
We have a "pure comparison" to Algernon's DMT angle for Ischemic Stroke.
Ninnion is a start up psychedelics biotech company established as recent as November 2020.
A read of their news release and website narrative for Ischemic Stroke is damn near the same script as Algernon.
https://newsdirect.com/news/psychedelic-pharmaceutical-startup-ninnion-announces-patent-filings-and-development-of-nin-s119-for-ischemic-stroke-796315381
As of now Ninnion plans a Phase 1 Ischemic Stroke clinical trial in Q1 2023. It will be a sure fire comparison to how they execute their timelines to data readouts at each stage.
Anyone willing to place a bet Ninnion will likely run circles around Algernon's timelines just as Bellus Health dors with Chronic Cough?
My guess is Ninnion will run clinical trials in good ole USA versus searching for cover high and low in any country other than North America.
Surely, there will be those laying claim and calling foul because Ninnion appears to be a private company. So what, it doesn't change the timeline comparison one iota.
Shout out to PretEnders @ stocktwits for the Due Diligence scoop.
Ninnion website: https://ninnion.com/aboutus/
There's a saying about it not being about how you start, but rather how you finish. In Algernon's case history, Algernon starts weak and finishes even weaker.
Happy Tuesday (Q2 2022),
M$
Very nicely done — Pennyland here but able to bank cash (and Pennyland all about selling shares to raise Cash needed to do what they say can be done)
Always take a Profit when Available - Doesn’t mean your done, just like the last run to $10 $AGNPF after low $4’s bought after Split
Watch the Insiders here - (4) now are touching the $6.27 $AGN off the Open Market
That’s $4.97 $AGNPF - but remember they gave themselves 96,000 Options @ $4.10 $AGN or $3.25 $AGNPF
Basically their paying $2.17 CAD over their Option Price of that $4.10 $AGN
+1 Extremely well said!
Almost No one posts here anymore. sadly true.
AGN's management,and their employees are doing the hard jobs attempting to produce 'stellar' results as a speculative pharma with the repurposed drug concept.
ON A MINIMAL Budget.
This is a Home Run or bust play for most as any speculative investment should be considered, IMO. (Some Trading at major events of course)
AGN has attracted Dr Strassman and other top names and medical institutions like Charles River Lab's and Hammerschmidt's involvement in the micro-dose / sub hallucinogenic use of DMT for the treatments of Strokes. The IP has been licensed and MOAs filed.
Dr. North is the consultant for the IP and MOAs involved with the Ifenprodil SCLC / Pancreatic Cancer Tumor treatments that has so far received support from the FDA.
Apparently, the trending from the IPF/CC clinical trial down under was strong enough to pursue full strength Cronic Cough clinical Trials.
AGN has again dug into the NASH re-purposed drug bag from Dr Mark Williams (merger) and is now pursuing CKD treatments. Dr Williams is on the BOD now.
I am holding AGN stock and may buy more depending on the winds. Cant see any reason to sell, especially now at this bottom created by the 'not stelar enough' results from our COVID trial, vaccines, BP and the share consolidation. Ouch,,, but there are new cards in play,,, with an IPO carrot,,, possibilities of a NASDAQ listing with success from any of the three THREE three paths. Financing at >$30+.?.$50.?.
I SEE THREE When/IF...?...GLTA...
This is SPECTOWN . .. My money, My responsibilities... GLTA...
2 COVID studies (SK & Romania) not powered for stat sig = Bogus
IPF/CC study not powered for stat sig = Bogus
Running clinical trials on the ultra cheap in Australia = Bogus
Claiming to bypass Phase 1 studies to go straight to Phase 2 = Bogus
Everybody wants in at Phase 2 = Bogus
65% chance of successful data readouts due to no safety concerns = Bogus
Equating the BS that comes out of Moron Moreau's pie hole on a regular basis to a Playing Card Dealer = Bizarre Bogus
There is a litany of shit Moeau has told shareholders that simply never held water.
One thing he didn't tell shareholders was he conducted private updates to BioPub subscribers.
Anyone have a clue why BioPub appears to no longer be on the Pennyland webcast list?
It probably has something to do with shareholders finally catching onto their conflict of interest collaboration.
Anybody here ever willing to stand up against that type of Bogus representation coming from management?
Crickets...
I thought so.
Do you and thank your lucky stars I'm gonna continue doing me.
M$
Who DEPENDS on others Due Diligence for understanding?
Who wears DEPENDS adult diapers?
Who enjoys apologizing and appeasing getting crapped on by Beer Buddy?
Nobody can stop insiders ilk/entourage from posting here.
Yeah, that's who!
Have fun,
M$
You have answers in black and white directly from the company. It's your interpretation of what's written that remains waaay off the mark. Also, this msg board has never had a large number of regular participants. Breathtec/Algernon has never captured the interest of the masses like a pot stock and now even a Psychedelic stock. That's a management problem not a msg board participation problem. If they had a "Winning Strategy" (a King Cobra quote) this msg board would likely be lit up like Christmas. Instead, you can always expect a lump of coal stuffed in your stock-ing @ Algernon Pharmaceuticals Inc. Management has driven the bus over the cliff and shareholders remain under the wreckage. Don't expect anyone to get too excited about Phase 1 clinical trials in 2023 and 2024 - because "Everybody Wants In At Phase 2" in 2026 or 2027 for data readouts.
M$
Continued answers based on opinions are speculation until reality occurs. No one is forced to accept the risks. No rewards or losses are guaranteed.
I sold my small piece of that comparison's stock. That doesn't mean a forever decision or some need to post a public kabitz on the way I 'might' have handled things IF I was the CEO. Certainly no need for publicly ranted tantrums.
Folks have to make decisions sometimes in spite of personal opinions or hope or attitudes. Doing nothing is also a decision. I have mentioned personal responsibility for actions before.
Any poster's claimed position, actions or opinionated hind-sights and speculations of different futures are all worth the same to others, IMHFO.
So sad there are many dissuaded from contributing to this forum...GLTA...
You continue to ask many of the same questions that have clear answers.
Have @ it
M$
Postscript
When I'm done posting here - I'm considering starting a blog with others for all things biotech - with a particular focus remaining on Algernon's haphazard journey.
@algernonpharma.com
Someone please tell Beer Buddy I said hello.
Which program or programs have been identified by AGN as the first with the needed MHRA/FDA approvals to move forward and specific plans the financing will cover.?.*
Just raise money on a handshake? 'Go for it guys', here's $9M.
$9M from one source, all at once, to spend any which way? From 'friends and family/cobras/Caymen Isls'.?. No specifics? No sponsors or partnerships? No plans, timelines or time for PR pumps to raise the PPS/MC first?
Investors and financiers usually support stocks they Like and understand. Plenty other stocks out there, no need to hate an investment, people can just sell, take a loss and not worry anymore. Holding is an active investment action.
*Financing a company's future efforts and goals is proportionately a much larger action? An IPO is an even larger action still, not some casual headfake.
But Interesting forecasts are allowed and the Right to 'opine' has been earned in blood and sacrifice in My America.
This shareholder expects microdose DMT through Hammerschmidt will be first program and have proper pump and circumstance.
...GLTA...
You think Algernon actually has competition? Yeah, we see how Algernon stacks up against companies that are winners like Bellus Health ($850M market cap/Chronic Cough) or GH Research ($1B market cap/one trick pony/ DMT). Those are real companies getting real value for shareholders. The type of "competition" Algernon wants to model is Xortx ($25M market cap/Chronic Kidney Disease). Xortx is a recently uplisted penny stock (sub $2 per share) trading on Nasdaq. Christopher Moreau recently hired their former CEO to "advise" on business strategy - smh.
Algernon is not competing with ANY company chasing after Cancer or any other disease given Algernon's foot dragging timelines to data readouts. I would have thought you were aware that there's more than one type of Cancer. Cancer competition? Also, you seem to want to understand a capital raise is coming with an uplist or not. My point has always remained the same here. I just keep explaining it to you over and over again. A capital raise is coming BEFORE any of the clinical trials are completed. They need money now - period.
(I'll reserve this space to say it all again a billion more times)
M$
Google the quote. I dont pump competition or comparisons.
That Capitol raise is Conditional on the move to nasdaq. Not before.......
Read...
What form of Cancer? Please name the company. Also, still haven't wrapped the mind around the fact the F-1 filing is the immediate avenue to a capital raise eh? Kinda crazy to think no uplist or capital raise will take place until after those Phase 1s are completed. It just shows no matter the efforts to explain the obvious it takes getting smacked between the eyes to clearly get the picture.
M$
As a comparison there is a company that "effectively destroyed cancer cells grown in culture" with a 4X+ in the last couple days. 70M MC and climbing.
AGN has gone past that milestone on ALL it's programs with murine testing (etc) and proof of concept/MOA enough to start New ones and move forward with other Human Clinical trials.
Pretty much a 'when' and 'which' question.
When that is set I hope for a much better PPS and leverage for raising money/IPO/2+ for 1...liquidity.?.
Second Phase 2 clinical trial data due.
So far.
A Full Plate for the next couple years.
A fair Speculative investment, IMO. I am holding. Every one has the Right to 'opine' their crystal balls...
...GLTA...
You do know it's an end of life story right? Kinda like compassionate use. It's not curing or eliminating anything but the patients worries. Whereas DMT for stroke is going after a treatment. Two completely different levels of hurdles to climb. However, surely the shrooms companies of the world, you know those with flying high all the time shareholders, will use it as some prop to pump their flailing stock.
Meanwhile, I'll take this opportunity to revise my own interpretive timeline for Algernon's pipeline. I continue to believe there will not be any clinical trials launched in 2022 other than DMT. The Cancer angles will be stalked just like DMT one quarter after the next (one more stalk and it will be a calendar year passing below your feet) until 2023. The Cancer angles will probably start sometime in 2023.
However, the start of the next Phase 2 study is thus far claimed to be DMT. I wouldn't expect Algernon to get to a data readout for DMT until Q4 2025 at best, but more likely in 2026. 2026 will be your 1st data readout powered for stat sig (maybe - gotta see it first) in the company's history. Moreau will have been at the helm going on 8 Years before he gets one real clinical trial completed at Phase 2 ("Everybody Wants In At Phase 2" - Moreau). It's the most pathetic timelines that are rife for minimum momentum and massive dilution.
Have @ it
M$
Outstanding: 1,674,868 on April 7, 2022
Monthly 5th Report for March
https://webfiles.thecse.com/3_-_Algernon_-_CSE_Form_7_-_March.pdf?DtvofF2uJlFLTw4rxAdgYDk6ArigM_Pd
Canada allows Psilocybin for terminal Cancer patients. Other indications to follow.?. Stroke?
Sub hallucinogenic dosed DMT @ Algernon, Clinical Trial applications' approval or denial due.
https://www.msn.com/en-us/money/other/6-terminally-ill-cancer-patients-in-canada-received-doses-of-the-psychoactive-substance-found-in-magic-mushrooms-after-authorities-eased-rules/ar-AAVXb5R?ocid=msedgdhp&pc=U531&cvid=799f8df25d2742ce99fa6e49b7e35605
Algernon Pharmaceuticals push back start of DMT Phase 1. First scheduled to start in Q4 2021 then Q1 2022 then Q2 2022. The latest SEC F-1 Filing now states DMT Phase 1 to start Q3 2022. Anyone have any guess on where DNT is headed next?
Yeah, all those Phase 1's look good on paper eh?
What I see is 3 multiple avenues of disappointment in 2022 just in time for the holidays as usual.
Of note: Uddin's market valuation ($33M) of Algernon Pharmaceuticals places ZERO value on any of the Phase 1 studies in the pipeline.
Uddin's entire valuation (paltry at best/sinister at worst) is based on the pending IPF/Chronic Cough data readout.
Andre Uddin is ranked in the Top 5 Percent among his Walk Street peers per "Toprank".
Crazy Ch!t A!nt !t
M$
Correction to last post added here:
Nobody cares about the approval of a Phase 1 study for DMT. So look to next year for any outside interest. Also, your 50M market cap number is one that no one has come up with yet.
Go back to Uddins 20 cent per share price target. That was based on 167M shares outstanding. That gets Uddins analysis to roughly $33M USD market cap.
Uddin places zero value on DMT or Cancer at Phase 1. Now take Uddins analysis and add 2.5x dilution to the equation. That's where this thing is headed!
To make it simple to comprehend (hopefully) is to take the original 167M shares and times it by 2.5 (2.5). That's the pre 100 to 1 reverse split calculation. Where now it's 1.67M shares times 2.5 (2.5).
Therefore, a $33M USD market cap (per Uddins analysis) with 4.175M shares outstanding is $7.90 per share price - effectively 7 cents pre reverse split.
Understanding the math provides you with a clearer picture - period. Management doesn't expect you to understand the math and the devastation the 100 to 1 reverse split has caused to shareholders.
Algernon will most likely fire sell shares around the $4 USD per share to get to it's $9M USD capital raise. Add another million shares for the cost of doing business. Hence, a $10M USD fire sale.
I come to these numbers using Uddins own numbers (Uddin is Algernon's go to guy) and the numbers represented in the F-1 filing to uplist to Nasdaq. I'm not flying off the handle here with wild and outlandish opinions.
If none of this "makes any cent's" to anyone - no worries. It will smack you right between the eyes soon enough. The Massive Dilution Train is a coming to your account soon.
Hard to believe I still do dis sh!t fo free.
Only In America!
M$
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |